Allergy

A wet spring last year made for ideal allergen-
creating conditions heading into summer 2011 — the growth of ragweed and an increase in mold. According to a Quest Diagnostics study published in 2011, sensitization to common ragweed has grown 15% nationally since 2000, while mold grew 12%. IMS Health projected a strong spring allergy season, especially across the north and northeast.


Asthma has been becoming more relevant in the nonprescription aisles of late. Even as Armstrong Pharmaceuticals phases out what was an almost $100 million-and-growing brand in Primatene Mist 
— the Food and Drug Administration has removed any inhalers containing 
chlorofluorocarbons from the market — homeopathic supplier King Bio is currently presenting an alternative in its AsthmaCare product.


As of the beginning of February, the cough-cold season had yet to materialize and illness levels were only just beginning to climb. If that’s the case, then an expected illness peak in late February/early March would make the 2011-2012 cough, cold and flu season one of the later-peaking seasons in recent years.


As of Jan. 21, overall incidence of upper respiratory illness this season was down 7.5% according to IMS Health, as compared with the 2010-2011 season.


PITTSBURGH — Mylan is changing the name of its branded specialty pharmaceutical business, the company said Wednesday.

The drug maker announced that it would change the name of Dey Pharma to Mylan Specialty. Dey makes treatments for respiratory diseases, psychiatric disorders and severe allergic reactions, including the EpiPen (epinephrine).

ALBUQUERQUE, N.M. — Heel last week launched Adrisin, a homeopathic medicine for the temporary relief of allergy symptoms, including runny nose, watery eyes, sneezing and skin irritations. Adrisin is packaged as a 15-count individually wrapped tablets.

ALLEGAN, Mich. — Perrigo is seeking approval from the Food and Drug Administration for a drug used to treat allergies in adolescents and adults, the company said Monday.

NEW YORK — A new study recently estimated that 5.9 million children in the United States suffer from a food allergy.

The study, published in the July issue of Pediatrics, also found that children with a tree nut or peanut allergy tend to have the most severe reactions, with nearly 39% of children ages 18 years and younger surveyed saying they had a severe or life-threatening allergy. Additionally, more than 30% of children surveyed said they suffered from multiple food allergies.

The study was funded by the Food Allergy Initiative.

In the year leading up to the switch of Allegra, Sanofi generated $214.2 million in U.S. prescription sales of Allegra, largely due to the generic competition against its Allegra D formulation. Now Sanofi is looking to virtually match those annual sales figures within the much more profitable nonprescription venue with the company’s successful switch from prescription to OTC this spring.